Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Stock Has Average Target Price of $17.67 According to Analysts

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) has received an average rating of “Moderate Buy” from the six analysts that are presently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $17.67.

Several equities analysts recently issued reports on AUPH shares. Royal Bank Of Canada boosted their price objective on Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the company a “sector perform” rating in a research report on Friday, August 7th. Bloom Burton upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 20th. Wall Street Zen downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Zacks Research lowered shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 21st. Finally, Weiss Ratings raised shares of Aurinia Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 26th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. acquired a new position in Aurinia Pharmaceuticals during the 2nd quarter worth approximately $139,037,000. Renaissance Technologies LLC lifted its position in shares of Aurinia Pharmaceuticals by 4.6% in the first quarter. Renaissance Technologies LLC now owns 1,663,835 shares of the biotechnology company’s stock worth $24,658,000 after purchasing an additional 73,700 shares in the last quarter. Allianz Asset Management GmbH acquired a new position in Aurinia Pharmaceuticals during the second quarter worth $14,284,000. Janus Henderson Group PLC boosted its holdings in Aurinia Pharmaceuticals by 9.7% during the first quarter. Janus Henderson Group PLC now owns 757,435 shares of the biotechnology company’s stock worth $11,225,000 after purchasing an additional 66,806 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its position in Aurinia Pharmaceuticals by 48.5% in the fourth quarter. BNP Paribas Financial Markets now owns 625,684 shares of the biotechnology company’s stock valued at $9,980,000 after purchasing an additional 204,326 shares in the last quarter. 36.83% of the stock is owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Price Performance

AUPH opened at $15.83 on Monday. The stock has a market cap of $2.11 billion, a P/E ratio of 6.91 and a beta of 1.60. Aurinia Pharmaceuticals has a 12 month low of $10.90 and a 12 month high of $19.25. The company has a quick ratio of 4.97, a current ratio of 5.42 and a debt-to-equity ratio of 0.07. The company has a fifty day simple moving average of $16.01 and a 200 day simple moving average of $15.83.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its earnings results on Thursday, August 6th. The biotechnology company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.04. The firm had revenue of $58.57 million for the quarter, compared to analyst estimates of $80.45 million. Aurinia Pharmaceuticals had a return on equity of 26.11% and a net margin of 100.84%. On average, research analysts expect that Aurinia Pharmaceuticals will post 0.9 EPS for the current year.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s primary product is Lupkynis (voclosporin), an oral calcineurin inhibitor used in combination with background immunosuppressive therapy to treat adult patients with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus.

Lupkynis was approved by the U.S. Food and Drug Administration in 2021 and subsequently authorized in Canada.